港股異動丨創科實業(0669.HK)大跌超12%領跌藍籌 北美疫情肆虐短期承壓
格隆匯3月23日丨今日大市下挫,創科實業(0669.HK)大跌12.19%暫領跌藍籌股,報42.85港元,暫成交4.97億港元,最新總市值782.33億港元。北美疫情持續惡化,加美邊界已於21日關閉。美國新冠肺炎確診病例高達35211例,已然成為重災區。集團主要業務為電動工具及地板護理兩大類別,銷售以北美市場為主。匯豐證券曾發佈研報稱,預期疫情在美國爆發將對創科實業旗下專業產品系列Milwaukee的銷售表現造成短期打擊,削目標價23%至60港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.